Biogen unveils promising new data for Salanersen in kids with SMA

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains

Alcon launches Hydrus Microstent in India to transform glaucoma care

The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes

Cirena licenses breakthrough RNA synthesis technology from CU Boulder

The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4

FDA okays JUXTAPID for kids with ultra-rare genetic cholesterol disorder

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia

Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications